Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Chemotherapy Relative Dose Intensity, Overall Survival, and Hematologic Toxicity in Solid-Tumor Cancer Patients: A Literature Review and Meta-Analysis

Lauren C Bylsma, MPH, Carrie M Nielson, PhD, Jon P Fryzek, Hossam A Saad, MD, Jeffrey Crawford, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-139279

Published: 2020

Journal Articles

Cost of Hospitalization in Patients with Cancer and Febrile Neutropenia and Impact of Comorbid Conditions

Gary H. Lyman, MD MPH, Marek S. Poniewierski, MD MS, Jeffrey Crawford, MD, David C. Dale, MD, Eva Culakova, PhD MS

Blood (2015) 126 (23): 2089.

https://doi.org/10.1182/blood.V126.23.2089.2089

Published: 2015

Journal Articles

Impact of Comorbidities on Length of Stay and Mortality in Hospitalized Patients with Cancer and Febrile Neutropenia

Eva Culakova, PhD MS, Marek S. Poniewierski, MD MS, Jeffrey Crawford, MD, David C. Dale, MD, Gary H. Lyman, MD MPH

Blood (2014) 124 (21): 2601.

https://doi.org/10.1182/blood.V124.21.2601.2601

Published: 2014

Journal Articles

Changing Patterns of Chemotherapy Delivery and Supportive Care for Aggressive B-Cell Non-Hodgkin's Lymphoma

Gary H. Lyman, MD, MPH, Jeffrey Crawford, MD, David C. Dale, MD, Sadie Whittaker, PhD, Dianne Tomita, MPH

Blood (2011) 118 (21): 2670.

https://doi.org/10.1182/blood.V118.21.2670.2670

Published: 2011

Journal Articles

Personalizing Cancer Supportive Care: Predicting Neutropenic Complications in Patients Receiving Intermediate Risk Cancer Chemotherapy

Gary H. Lyman, MD, MPH, Eva Culakova, PhD, MS, Marek S. Poniewierski, MD, MS, Jeffrey Crawford, MD, David C. Dale, MD, Nicole M. Kuderer, MD

Blood (2011) 118 (21): 1022.

https://doi.org/10.1182/blood.V118.21.1022.1022

Published: 2011

Journal Articles

Overall Survival of Lymphoma Patients In Randomized Controlled Trials Comparing Primary G-CSF Chemotherapy Support to Control.

Gary H. Lyman, MD, MPH, Jeffrey Crawford, Eva Culakova, PhD, MS, Marek S. Poniewierski, MD, MS, Mingyan Huang, Nicole M. Kuderer, MD, David C. Dale, MD

Blood (2010) 116 (21): 1502.

https://doi.org/10.1182/blood.V116.21.1502.1502

Published: 2010

Journal Articles

Acute Myeloid Leukemia or Myelodysplastic Syndromes and All-Cause Mortality in Randomized Controlled Trials of Cancer Patients Receiving Chemotherapy with or without Granulocyte Colony-Stimulating Factor: A Systematic Review and Meta-Analysis.

Gary H. Lyman, MD, MPH, Jeffrey Crawford, MD, Eva Culakova, PhD, MS, Marek S. Poniewierski, MD, MS, Debra Wolff, MS, PCNP, Nicole M. Kuderer, MD, David C. Dale, MD

Blood (2009) 114 (22): 3100.

https://doi.org/10.1182/blood.V114.22.3100.3100

Published: 2009

Journal Articles

Elafin Is a Biomarker of Graft Versus Host Disease of the Skin

Sophie Paczesny, MD, PhD., John E. Levine, MD, Jason Hogan, PhD., Jeffrey Crawford, Thomas Braun, PhD, Hong Wang, PhD., Vitor Faca, PhD, Qing Zhang, Sharon Pitteri, PHD, Alice Chin, Sung Choi, MD, Carrie Kitko, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Shin Mineishi, MD, Joel Whitfield, Dawn Jones, RN, Samir Hanash, MD, PhD, James L.M. Ferrara, MD

Blood (2008) 112 (11): 716.

https://doi.org/10.1182/blood.V112.11.716.716

Published: 2008

Journal Articles

Final Risk Prediction Model for Neutropenic Complications in Patients Receiving Cancer Chemotherapy

Gary H. Lyman, MD, MPH, Jeffrey Crawford, MD, Nicole M. Kuderer, MD, Debra Wolff, MS, PCNP, Eva Culakova, PhD, MS, Marek S. Poniewierski, MD, MS, David C. Dale, MD

Blood (2008) 112 (11): 1312.

https://doi.org/10.1182/blood.V112.11.1312.1312

Published: 2008

Journal Articles

Standard Versus Dose-Intensified Chemotherapy with Granulocyte Colony-Stimulating Factor for Malignant Lymphoma: Evaluation of Risk for Acute Myeloid Leukemia or Myelodysplastic Syndrome

Gary H. Lyman, MD, MPH, David C. Dale, MD, Debra Wolff, MS, PCNP, Eva Culakova, PhD, MS, Nicole M. Kuderer, MD, Marek S. Poniewierski, MD, MS, Jeffrey Crawford, MD

Blood (2008) 112 (11): 2390.

https://doi.org/10.1182/blood.V112.11.2390.2390

Published: 2008

Journal Articles

A Conditional Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.

Gary H. Lyman, MD, MPH, FRCP, Jeffrey Crawford, MD, Nicole M. Kuderer, MD, Debra A. Wolff, PCNP, Eva Culakova, PhD, Marek S. Poniewierski, MD, MS, David C. Dale, MD

Blood (2007) 110 (11): 372.

https://doi.org/10.1182/blood.V110.11.372.372

Published: 2007

Journal Articles

Prospective Validation of a Predictive Model for Early Anemia in Patients Receiving Cancer Chemotherapy.

Gary H. Lyman, MD, MPH, FRCP, David C. Dale, MD, Nicole M. Kuderer, MD, Debra A. Wolff, MS, PCNP, Eva Culakova, PHD, Marek S. Poniewierski, MD, MS, Jeffrey Crawford, MD, for the ANC Study Group

Blood (2006) 108 (11): 460.

https://doi.org/10.1182/blood.V108.11.460.460

Published: 2006

Journal Articles

A Prospective Risk Model for Neutropenic Complications in Patients with Malignant Lymphoma.

Gary H. Lyman, MD, MPH, Jeffrey Crawford, MD, Debra Wolff, MS, PCNP, Eva Culakova, PhD, Marek S. Poniewierski, MD, MS, David C. Dale, MD

Blood (2005) 106 (11): 3328.

https://doi.org/10.1182/blood.V106.11.3328.3328

Published: 2005

Journal Articles

Dose Intensity and Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy.

Michelle Shayne, MD, Eva Culakova, Ph.D, Marek S. Poniewierski, MD, MS, Debra Wolff, MS, PCNP, David C. Dale, MD, Jeffrey Crawford, MD, Gary H. Lyman, MD, MPH

Blood (2005) 106 (11): 3124.

https://doi.org/10.1182/blood.V106.11.3124.3124

Published: 2005

Journal Articles

A Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.

Gary H. Lyman, MD, MPH, Brandon McMahon, MD, Nicole M. Kuderer, MD, Jeffrey Crawford, MD, Debra Wolff, MS, PCNP, Eva Culakova, PhD, Marek S. Poniewierski, MD, MS, David C. Dale, MD

Blood (2005) 106 (11): 754.

https://doi.org/10.1182/blood.V106.11.754.754

Published: 2005

Journal Articles

Validation of a Risk Model for Hospitalized Adult Cancer Patients with Febrile Neutropenia.

Nicole M. Kuderer, MD, Jeffrey Crawford, MD, David C. Dale, MD, Gary H. Lyman, MD, MPH, for the ANC Study Group

Blood (2004) 104 (11): 89.

https://doi.org/10.1182/blood.V104.11.89.89

Published: 2004

Journal Articles

Reduced Relative Dose Intensity (RDI) in Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL).

David C. Dale, MD, Jerome H. Goldschmidt, MD, Jeffrey Crawford, MD, Gary H. Lyman, MD, MPH, for the ANC Study Group

Blood (2004) 104 (11): 3314.

https://doi.org/10.1182/blood.V104.11.3314.3314

Published: 2004

Journal Articles

Predicting the Risk of Neutropenic Complications and Reduced Dose Intensity in Patients with Malignant Lymphoma: Results from a Prospective Study.

David C. Dale, MD, Jeffrey Crawford, MD, Debra A. Wolff, MS, PCNP, Marek S. Poniewierski, MD, MS, Eva Culakova, PHD, Gary H. Lyman, MD, MPH, for the ANC Study Group

Blood (2004) 104 (11): 4599.

https://doi.org/10.1182/blood.V104.11.4599.4599

Published: 2004

Journal Articles

Assessment of Hematologic and Non-Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Registry.

Naeem Tahir, MD, Jerome H. Goldschmidt, MD, Eva Culakova, PHD, Marek S. Poniewierski, MD, MS, Debra A. Wolff, MS, PCNP, David C. Dale, MD, Jeffrey Crawford, MD, Gary H. Lyman, MD, MPH

Blood (2004) 104 (11): 3131.

https://doi.org/10.1182/blood.V104.11.3131.3131

Published: 2004

Journal Articles

First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.

Jeffrey Crawford, MD, Debra A. Wolff, MS, PCNP, Eva Culakova, PhD, Marek S. Poniewierski, MD, MS, Caleb Selby, David C. Dale, MD, Gary H. Lyman, MD, MPH, for the ANC Study Group

Blood (2004) 104 (11): 2210.

https://doi.org/10.1182/blood.V104.11.2210.2210

Published: 2004

NARROW

Chemotherapy Relative Dose Intensity, Overall Survival, and Hematologic Toxicity in Solid-Tumor Cancer Patients: A Literature Review and Meta-Analysis

Cost of Hospitalization in Patients with Cancer and Febrile Neutropenia and Impact of Comorbid Conditions

Impact of Comorbidities on Length of Stay and Mortality in Hospitalized Patients with Cancer and Febrile Neutropenia

Changing Patterns of Chemotherapy Delivery and Supportive Care for Aggressive B-Cell Non-Hodgkin's Lymphoma

Personalizing Cancer Supportive Care: Predicting Neutropenic Complications in Patients Receiving Intermediate Risk Cancer Chemotherapy

Overall Survival of Lymphoma Patients In Randomized Controlled Trials Comparing Primary G-CSF Chemotherapy Support to Control.

Acute Myeloid Leukemia or Myelodysplastic Syndromes and All-Cause Mortality in Randomized Controlled Trials of Cancer Patients Receiving Chemotherapy with or without Granulocyte Colony-Stimulating Factor: A Systematic Review and Meta-Analysis.

Elafin Is a Biomarker of Graft Versus Host Disease of the Skin

Final Risk Prediction Model for Neutropenic Complications in Patients Receiving Cancer Chemotherapy

Standard Versus Dose-Intensified Chemotherapy with Granulocyte Colony-Stimulating Factor for Malignant Lymphoma: Evaluation of Risk for Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Conditional Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.

Prospective Validation of a Predictive Model for Early Anemia in Patients Receiving Cancer Chemotherapy.

A Prospective Risk Model for Neutropenic Complications in Patients with Malignant Lymphoma.

Dose Intensity and Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy.

A Risk Model for Chemotherapy-Induced Anemia (CIA) in Cancer Patients.

Validation of a Risk Model for Hospitalized Adult Cancer Patients with Febrile Neutropenia.

Reduced Relative Dose Intensity (RDI) in Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL).

Predicting the Risk of Neutropenic Complications and Reduced Dose Intensity in Patients with Malignant Lymphoma: Results from a Prospective Study.

Assessment of Hematologic and Non-Hematologic Toxicity in Older Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Registry.

First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results from a Prospective Nationwide Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only